For Anxiety For Depression For Insomnia Alpha-Stim

Similar documents
33 % of whiplash patients develop. headaches originating from the upper. cervical spine

Cranial Electrotherapy Stimulation for Treatment of Anxiety, Depression, and Insomnia

Measurement Tool for Clinical Practice Guideline Implementation: Measures for Depression

Naltrexone and Alcoholism Treatment Test

ADHD PRACTISE PARAMETER. IRSHAAD SHAFFEEULLAH, M.D. A diplomate American Board of CHILD AND ADOLESCENT PSYCHIATRY

Tara Stevermuer (MAppStat), Centre for Health Service Development, University of Wollongong.

Best Practices Treatment Guideline for Major Depression

Corporate Medical Policy

Canines and Childhood Cancer

DEPRESSION Depression Assessment PHQ-9 Screening tool Depression treatment Treatment flow chart Medications Patient Resource

Collaborative Care: Evidence-Based Mental Health Care in Primary Care Settings

ADVISORY OPINION THE USE OF CONTROLLED SUBSTANCES FOR THE TREATMENT OF CHRONIC PAIN

Cognitive Rehabilitation of Blast Traumatic Brain Injury

2012 Global Neuro-psychiatric Devices New Product Innovation Award

The UPMC Advantage: What It Means to the Applicant Workers' Compensation Attorney

Integrative Therapies and Preconception Health. Debbie Ringdahl DNP, RN, CNM

PSYCHOLOGICAL AND NEUROPSYCHOLOGICAL TESTING

Treatment for substance abuse and dependence at HC Marbella

Susan Rindt, PsyD SUMMARY EDUCATION CLINICAL EXPERIENCE. Markdown -> PDF, HTML, and more

KENTUCKY ADMINISTRATIVE REGULATIONS TITLE 201. GENERAL GOVERNMENT CABINET CHAPTER 9. BOARD OF MEDICAL LICENSURE

Noninvasive Neuromodulation in Psychiatric Treatment: Current and Developing

Guidelines for Use of Controlled Substances for the Treatment of Pain

INTERNSHIP University Hospital/Oklahoma Health Sciences Center Oklahoma City, Oklahoma

Michigan Guidelines for the Use of Controlled Substances for the Treatment of Pain

Mellen Center for Multiple Sclerosis

Cranial Electrotherapy Stimulation for Anxiety, Depression, Insomnia, Cognitive Dysfunction, and Pain: A Review and Meta-Analyses

Psychopharmacotherapy for Children and Adolescents

!!!!!!!!!!!! Liaison Psychiatry Services - Guidance

Symptom Based Alcohol Withdrawal Treatment

IMR ISSUES, DECISIONS AND RATIONALES The Final Determination was based on decisions for the disputed items/services set forth below:

American Society of Addiction Medicine

Department of Health Sciences

STUDY PLAN Master Degree in Clinical Nursing/ Palliative Care (Thesis )

Antipsychotic drug prescription for patients with dementia in long-term care. A practice guideline for physicians and caregivers

Guidelines for the Use of Controlled Substances in the Treatment of Pain Adopted by the New Hampshire Medical Society, July 1998

ADVISORY OPINION THE USE OF CONTROLLED SUBSTANCES FOR THE TREATMENT OF CHRONIC PAIN

Is electrotherapy more effective than other physical therapy approaches in reducing pain and disability in adults with supraspinatus tendonitis?

Chemobrain. Halle C.F. Moore, MD The Cleveland Clinic October 3, 2015

MULTIPLE SCLEROSIS AND DEPRESSION. Michael Racke, MD The Ohio State University Meera Narasimhan, MD University of South Carolina

The purpose of this policy is to describe the criteria used by BHP in medical necessity determinations for inpatient CH treatment services.

About brief Affect Regulation Therapy (A.R.T.) 1

Comorbid Conditions in Autism Spectrum Illness. David Ermer MD June 13, 2014

There is a growing focus on moving upstream to protect mental health and reduce the incidence of mental illness.

Master of Nursing. The Chinese University of Hong Kong The Nethersole School of Nursing

The LifeWave ALAVIDA Non-transdermal Antiaging Patch Improves Cellular Functional Status in Different Organs

IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF PENNSYLVANIA UNITED STATES OF AMERICA : CRIMINAL NO. v.

Depression & Multiple Sclerosis

Monash University - Master of Clinical Pharmacy

qeeg-guided NEUROFEEDBACK REHABILITATION

Depression & Multiple Sclerosis. Managing Specific Issues

American Psychological Association D esignation Criteria for Education and

Managing depression after stroke. Presented by Maree Hackett

Preservation and Incorporation of Valuable Endoscopic Innovations (PIVI)

Registered Charity No. 5365

02 DEPARTMENT OF PROFESSIONAL AND FINANCIAL REGULATION

(Validfrom 01.august2015un lfurtherno ce)

The NYU Caregiver Intervention

Human Capital Development & Education Program Proposal

Wellness for People with MS: What do we know about Diet, Exercise and Mood And what do we still need to learn? March 2015

Clinical Practice Guidelines: Attention Deficit/Hyperactivity Disorder

Tai Chi: : A Mind-body Exercise for Pain Relief and Well-being

Psychology and Aging. Psychologists Make a Significant Contribution. Contents. Addressing Mental Health Needs of Older Adults... What Is Psychology?

DEPRESSION CARE PROCESS STEP EXPECTATIONS RATIONALE

MANUEL DAVID TOBIAS, Ph.D Town Centre Dr. Suite 875 San Diego, California Phone Fax

Requirements for the American Board of Sleep Medicine Behavioral Sleep Medicine Certification Examinations

Algorithm for Initiating Antidepressant Therapy in Depression

Preferred Practice Guidelines Bipolar Disorder in Children and Adolescents

PAIN MANAGEMENT AT UM/SYLVESTER

Seminar/Talk Calendar

Nurse Practitioner Student Learning Outcomes

Treatment of Chronic Pain: Our Approach

General Hospital Information

Assessment and Diagnosis of DSM-5 Substance-Related Disorders

PCHC FACTS ABOUT HEALTH CONDITIONS AND MOOD DIFFICULTIES

Neal R. Morris, Ed.D., M.S. Child and Family Psychology Health Psychology

BEACON HEALTH STRATEGIES, LLC TELEHEALTH PROGRAM SPECIFICATION

CHRONIC PAIN AND RECOVERY CENTER

Meditation as Viable

03/20/12. Recognize the right of patients to appropriate assessment and management of pain

WHAT EVERY PSYCHOLOGIST SHOULD KNOW ABOUT GUIDED IMAGERY

Dependence and Addiction. Marek C. Chawarski, Ph.D. Yale University David Metzger, Ph.D. University of Pennsylvania

CARE MANAGEMENT FOR LATE LIFE DEPRESSION IN URBAN CHINESE PRIMARY CARE CLINICS

Depression. Introduction Depression is a common condition that affects millions of people every year.

Treating Depression to Remission in the Primary Care Setting. James M. Slayton, M.D., M.B.A. Medical Director United Behavioral Health

What you should know about treating your pain with opioids. Important information on the safe use of opioid pain medicine.

MOH CLINICAL PRACTICE GUIDELINES 2/2008 Prescribing of Benzodiazepines

Cognitive Assessment and Rehabilitation in mtbi Patients. Shannon E. Auxier, MS CCC-SLP Judy M. Mikola, PhD CCC-SLP

NEUROSCIENCE. THE POWER OFxTM. Experts. Experience. Execution. Medpace Neuroscience Expertise. medpace.com

THE OFFICE OF SUBSTANCE ABUSE SERVICES REQUIREMENTS FOR THE PROVISION OF RESIDENTIAL DETOXIFICATION SERVICES BY PROVIDERS FUNDED WITH DBHDS RESOURCES

1695 N.W. 9th Avenue, Suite 3302H Miami, FL Days and Hours: Monday Friday 8:30a.m. 6:00p.m. (305) (JMH, Downtown)

Transcription:

LET NOTHING STOP THEM. For Anxiety For Depression For Insomnia Alpha-Stim Alpha-Stim AID

LET NOTHING STOP THEM. Relieve your patients symptoms of anxiety, depression, and insomnia, quickly and safely, with Alpha-Stim. The Alpha-Stim AID is a Cranial Electrotherapy Stimulation* (CES) device that uses low-level electrical current to safely and effectively treat anxiety, depression, and insomnia. Alpha-Stim treatments are cumulative; however, most patients show at least some improvement after the first treatment. Alpha-Stim technology is safe, with no serious adverse events reported in over years of clinical use. Alpha-Stim devices can be used as a first-line therapy or as an adjunct to pharmacotherapy (without polypharmacy effects). * Initially cleared for marketing by the FDA in 1992 as a prescriptive, noninvasive treatment, Alpha-Stim has an extensive safety record, with few side effects (less than 1%) and considerable scientific evidence of the significant results patients can achieve.

THE FOUNDATION: A Patented Waveform Effectively targets cell receptors, activating them through frequency matching in a manner similar to chemical ligands Delivers a very low level of current in pulsed microcurrents of less than one milliampere Provides a wide range of biological frequencies that no other device can emulate The only rigorously tested waveform designed and refined to improve effectiveness THE IMPACT: An Electrical Intervention The brain functions electrochemically and can be readily modulated by electrical intervention 1,2 Alpha-Stim impacts the electrochemical function of the brain to improve patients emotional and physiologic states Designed to affect the activity of subcortical brain structures known to regulate emotions fmri studies demonstrate the waveform current changes the appropriate brain structures THE RESULTS: Significant Improvement, Quickly, with Lasting Effect As the leader in CES, Alpha-Stim has helped clinicians around the world offer fast, safe, and effective relief for patients suffering from anxiety, depression, and insomnia. qeeg changes in subjects treated with minutes of Alpha-Stim CES. There is an increase (red) in alpha activity with a simultaneous decrease (blue) in beta and delta. 2

PROVEN: Alpha-Stim Significantly Reduces Anxiety Symptoms MEAN ANXIETY SCORES OVER 5 WEEKS GENERAL ANXIETY SCORES MEAN ANXIETY SCORES REDUCTION POST TREATMENT Mean Anxiety Scores 25 15 27.6 29.5 22 19.9 BASELINE WEEK 1 WEEK 3 WEEK 5 Active General Anxiety Disorder, HAM-A, 5 Weeks, N=8 Liberty and Stetson Universities 19.9 16.1 Sham *p<0.001 d=0.94 13.4* 70 60 50 40 62.3 BASELINE General Anxiety Disorder, HAM-A, 5 Weeks, N=8 Liberty and Stetson Universities ENDPOINT 14.8* *p=0.05 Mean Anxiety Scores 3 2.5 2 1.5 2.76 1.24* 1.5 0.0 CES SHAM Post Alpha-Stim CES Treatment Likert Scale, 2 Treatments, N=50 *p=0.01 After 5 weeks of treatment, the active Alpha-Stim CES group reported an average decrease of 94% in their anxiety 3 By tracking the anxiety levels of patients over 6 months, Alpha-Stim was reported to reduce feelings of anxiety by an average of 76% 4 In a study of preoperative anxiety, Alpha-Stim recipients reported significantly less anxiety after one minute application 5 PROVEN: Alpha-Stim Significantly Reduces Insomnia CHANGE IN TOTAL SLEEP TIME GENERAL SLEEP DISTURBANCE IMPROVED SLEEP QUALITY Change in Total Sleep Time 50 40 0 - - - 43 CES Total Sleep Time, 5 Days, N=57 Walter Reed National Military Medical Center -19 SHAM General Sleep Disturbance Scale 6.00 5.00 4.00 3.00 2.00 1.00 0 0 2 4 6 8 WEEKS Active Sham Usual Care Adjusted Means Sleep Quality 6 5 4 3 2 1 0 5.2* ACTIVE Endpoint of Study 3.3 SHAM *p=0.02 Alpha-Stim CES recipients demonstrated an average increase of 43 total minutes of sleep time after only 5 treatments **6 Alpha-Stim CES reduced patient sleep disturbances, completing this 8-week study with scores below the range of insomnia **7 Alpha-Stim CES recipients reported a 36% improvement in quality of sleep compared to sham recipients **8 **Insomnia reduction varies widely, with some individuals having improved sleep immediately and others not having improved sleep until weeks into treatment.

PROVEN: Alpha-Stim Significantly Reduces Depression Symptoms Depression Mean Improvement 15 14 13 12 11 9 8 7 6 MEAN IMPROVEMENT IN DEPRESSION 14.5 13.2 BASELINE.2 9.6 WEEK 1 Active Depression Patients, HAM-D17, 5 Weeks, N=8 Liberty and Stetson Universities 9.9 8.1 WEEK 3 Sham After 5 weeks of treatment, the active Alpha-Stim CES group reported an average decrease of 75% in their depression 3 *p<0.001 d=0.75 WEEK 5 6.5* Mean Depression Scores 11 9 8 7 6 5 REDUCED DEPRESSION SCORES.5 BASELINE Depression Patients, HAM-D17, 6 Weeks, N=9 University of California at Los Angeles 6* ENDPOINT After 6 weeks of treatment, Alpha-Stim users experienced a 42.8% improvement 9 HELP FOR YOUR PATIENTS SUFFERING FROM ANXIETY, DEPRESSION, AND INSOMNIA IS HERE. Getting started with Alpha-Stim To offer Alpha-Stim to your patients, contact your Alpha-Stim representative or visit Alpha-Stim.com. We offer free trials to licensed practitioners. Typically, an in office or clinic trial can identify those individuals who readily respond to treatment. Mean Depression Scores MIXED ANXIETY AND DEPRESSION DISORDER 5 WEEKS 0.65 0.60 0.55 0.50 0.64 PRE POST 0.52* After only 5 days of therapy with Alpha-Stim, the effective rate was 94% *p<0.01 Mixed Anxiety and Depression Disorder, Xung Depression Scale, 5 Treatments, N=32 Children Beijing Children s Hospital MIXED ANXIETY AND DEPRESSION 3 WEEKS TREATMENT Mean Depression Scores 55 50 45 40 35 49.6 47.2 46.8 PRE Active Sham POST 34.1* *p<0.001 Mixed Anxiety and Depression Disorder, Zung Depression Scale, 15 Treatments, N=60 Children Nanjing Medical University After 3 weeks of treatment with Alpha-Stim, active (but not sham) participants achieved significant improvement in depressive symptoms 11 Ordering through Alpha-Stim.com is easier than ever. You or your patients can fulfill your order for Alpha-Stim through our online store, through your local authorized Alpha-Stim representative, or by calling our customer service center. Alpha-Stim is ideal for clinical or home use. Safe and easy to use in the office or at home, Alpha-Stim is cost-effective compared with drugs and other devices used to treat similar symptoms. The proprietary Alpha-Stim waveform is supported by more scientific research than any therapeutic medical device in its class. For additional clinical research, contact your Alpha-Stim representative. LET NOTHING STOP THEM.

Alpha-Stim M Alpha-Stim AID ABOUT ELECTROMEDICAL PRODUCTS INTERNATIONAL, INC: A Dedicated Company You Can Trust Electromedical Products International, Inc. (EPI) was founded in 1981 by Dr. Daniel L. Kirsch, a world-renowned neurobiologist, who developed a safe and effective solution for the treatment of pain, sleep, and mood disorders with Alpha-Stim technology. He was the recipient of the 08 prestigious Richard S. Weiner Pain Educator of the Year Award from the American Academy of Pain Management. EPI was a recipient of the 13 Best of Business Award in the Surgical and Medical Instruments category by the Small Business Commerce Association (SBCA), and holds multiple patents. Today, EPI is a global enterprise with representatives throughout the world, with staff dedicated to the pursuit of excellence in the treatment and diagnosis of medical and healthcare-related issues. EPI is a FDA registered establishment with operations certified by an independent third party to the International Standards Organization (ISO) 13485:03 standards for quality in medical devices. Alpha-Stim products earned and maintain the CE mark through the European Medical Device Directive and are FDA-cleared for marketing. REFERENCES 1. Heffernan M. Comparative effects of microcurrent stimulation on EEG spectrum and correlation dimension. Integrative Physiological and Behavioral Science. 1996;31(3):2-9. 2. Kennerly R. Changes in quantitative EEG and low resolution tomography following cranial electrotherapy stimulation. PhD Dissertation, the University of North Texas. 06;529 pp., 81 tables, 233 figures, 171 references. 3. Barclay TH, Barclay RD. A clinical Trial of cranial electrotherapy stimulation for anxiety and comorbid depression. Journal of Affective Disorders. 14;164:171-177. Presented at the American Psychological Association National Conference, Honolulu, July 13. 4. Overcash SJ. Cranial electrotherapy stimulation in patients suffering from acute anxiety disorders. American Journal of Electromedicine. 1999;16(1):49-51. 5. Lee SH, Kim, WY, Lee CH, et al. Effects of cranial electrotherapy stimulation on preoperative anxiety, pain and endocrine response. Journal of International Medical Research. 13;41(6) 1788-1795. 6. Lande RG, Gragnani C. Efficacy of cranial electric stimulation for the treatment of insomnia: A randomized pilot study. Complementary Therapies in Medicine. 13;21(1):8-13. 7. Taylor AG, Anderson JG, Riedel SL, et al. Cranial electrical stimulation improves symptoms and functional status in individuals with fibromyalgia. Pain Management Nursing. 13;Dec;14(4):327-35. 8. Lichtbroun AS, Raicer MMC, Smith RB. The treatment of fibromyalgia with cranial electrotherapy stimulation. Journal of Clinical Rheumatology. 01;7(2):72-78. 9. Bystritsky A, Kerwin L, Feusner J. A pilot study of cranial electrotherapy stimulation for generalized anxiety disorder. Journal of Clinical Psychiatry. 08;69:412-417. Presented at the American Psychiatric Association meeting, San Fransicso, 09.. Lu XY, Wang AH, Li Y, et al. Safety and effectiveness of cranial electrotherapy stimulation in treating children with emotional disorders. Chinese Journal of Clinical Rehabilitation. 05;9(8):96-7. 11. Chen Y, Yu L, Zhang J, et al Results of cranial electrotherapy stimulation to children with mixed anxiety and depressive disorder. Shanghai Archives of Psychiatry. 07;19(4):3-5. Authorized Representative for the European Union: MediMark Europe 11, rue Émile Zola BP 2332/38033 Grenoble Cedex2 France Tél: +33 (0)4 76 86 43 22 / Fax: +33 (0)4 76 17 19 82 E-Mail: info@medimark-europe.com REV A Alpha-Stim and the Alpha-Stim logo are registered trademarks, and LET NOTHING STOP THEM is a trademark of Electromedical Products International, Inc. 14 Electromedical Products International, Inc. All rights reserved. Manufactured under US Patents 8,612,008 and 8,457,765. Type B Equipment. This stimulator is internally powered only. See instructions for use. Read the manual thoroughly before using. Manufactured and marketed by: Electromedical Products International, Inc. 21 Garrett Morris Parkway Mineral Wells, TX 76067-9034 USA 1-800-FOR-PAIN (367-7246) in USA Tel: + (940) 328-0788 (Outside USA) Fax: (940) 328-0888 www.alpha-stim.com